This grant is for establishing a large-scale (over 50,000 persons) national longitudinal cohort of repeat blood donors. The purpose is to monitor changes in antibody titers against common and novel respiratory viruses, including SARS-CoV-2, RSV, and Influenza. This initiative will enable the estimation of incident infection burden, determination of antibody protection thresholds, assessment of state- or region-specific population immunity, and tracking of waning immunity amidst viral evolution. Donors will also be surveyed for risk factors, vaccination status, and symptoms, with a repository established for future immunological analyses. This research builds on successful CDC serosurveillance efforts during the COVID-19 pandemic.
Opportunity ID: 350452
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-IP-24-046 |
| Funding Opportunity Title: | Nationwide Cohort to Estimate Burden of Respiratory Viruses and Immunologic Response (Blood Donor Cohort) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.083 — Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 12, 2023 |
| Last Updated Date: | Dec 12, 2023 |
| Original Closing Date for Applications: | Feb 16, 2024 Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. |
| Current Closing Date for Applications: | Feb 16, 2024 Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. |
| Archive Date: | Mar 17, 2024 |
| Estimated Total Program Funding: | $26,500,000 |
| Award Ceiling: | $4,500,000 |
| Award Floor: | $3,000,000 |
Eligibility
| Eligible Applicants: | City or township governments County governments State governments Special district governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | This project would establish and sustain a national longitudinal cohort of repeat blood donors with the purpose of monitoring changes in antibody titers against common or novel respiratory viruses; surveying the donors to assess for risk factors for infection, vaccination status, respiratory symptoms, and severe illness; and establishing a repository for further analysis as new assays to measure the immune response to respiratory virus infections are developed.During the COVID-19 pandemic, CDC used a contract mechanism to fund national serosurveillance studies, which used regular antibody assessments and surveys to monitor the burden of infection, risk factors for infection, and explore the duration and extend of immunity by population throughout the US (2020-2022). By 2022, algorithms for using quantitative antibody titers to detect reinfection were established and tested, creating novel systems for monitoring burden even in the setting of high overall seroprevalence.Adapting these tools to the current context, this research cooperative agreement would establish a large-scale longitudinal cohort (>50,000 persons) of repeat blood donors with the purpose of: 1) estimating the national burden of incident SARS-CoV-2 infection, and further adapting the approach to other respiratory viruses as technology allows including Respiratory Syncytial Virus, Influenza, Human Metapneumovirus, EVD-68, and others; 2) determining antibody thresholds for protection across multiple respiratory viruses; 3) assessing state- or region-specific population-level immunity to/risk for infection through tracking median antibody titers within various populations; and 4) monitoring waning immunity and changes in immune capabilities in the context of ongoing viral evolution. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Dr. Jamal Bankhead
JBankhead@cdc.gov Email:JBankhead@cdc.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 350452 Full Announcement-Full Announcement -> Foa_Content_of_RFA-IP-24-046 Final.pdf
Packages
| Agency Contact Information: | Dr. Jamal Bankhead JBankhead@cdc.gov Email: JBankhead@cdc.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.083 | RFA-IP-24-046 | Nationwide Cohort to Estimate Burden of Respiratory Viruses and Immunologic Response (Blood Donor Cohort) | PKG00284144 | Dec 12, 2023 | Feb 16, 2024 | View |
Package 1
Mandatory forms
350452 RR_SF424_5_0-5.0.pdf
350452 PHS398_CoverPageSupplement_5_0-5.0.pdf
350452 RR_OtherProjectInfo_1_4-1.4.pdf
350452 PHS398_ResearchPlan_5_0-5.0.pdf
350452 PerformanceSite_4_0-4.0.pdf
350452 RR_KeyPersonExpanded_4_0-4.0.pdf
350452 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
350452 RR_Budget_3_0-3.0.pdf
Optional forms
350452 RR_SubawardBudget30_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
